Holen Sie sich die Stockscreener-App
0.8977
0.26%
-0.0023
Handel nachbörslich:
.90
0.0023
+0.26%
Schlusskurs vom Vortag:
$0.90
Offen:
$0.8898
24-Stunden-Volumen:
528.29K
Relative Volume:
0.29
Marktkapitalisierung:
$75.82M
Einnahmen:
$153.73M
Nettoeinkommen (Verlust:
$-106.79M
KGV:
-0.5043
EPS:
-1.78
Netto-Cashflow:
$-115.93M
1W Leistung:
-2.42%
1M Leistung:
+2.63%
6M Leistung:
-66.12%
1J Leistung:
-79.27%
1-Tages-Spanne:
$0.86
$0.9105
1-Wochen-Bereich:
$0.86
$0.9599
52-Wochen-Spanne:
$0.5231
$5.17
Sutro Biopharma Inc Stock (STRO) Company Profile
Firmenname
Sutro Biopharma Inc
Sektor
Branche
Telefon
650-392-8412
Adresse
111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Vergleichen Sie STRO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
STRO
Sutro Biopharma Inc
|
0.8977 | 77.70M | 153.73M | -106.79M | -115.93M | -1.78 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Sutro Biopharma Inc Stock (STRO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-17 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-03-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2025-03-14 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | Herabstufung | Wedbush | Outperform → Neutral |
| 2024-05-08 | Eingeleitet | BofA Securities | Buy |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-06 | Eingeleitet | Oppenheimer | Outperform |
| 2023-03-21 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-08-18 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-06-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-09-02 | Eingeleitet | Jefferies | Buy |
| 2020-07-16 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-13 | Eingeleitet | SunTrust | Buy |
| 2019-10-07 | Eingeleitet | BTIG Research | Buy |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2019-04-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-10-22 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2018-10-22 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-10-22 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Sutro Biopharma Inc Aktie (STRO) Neueste Nachrichten
Northern Trust Corp Buys 14,492 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
BNP Paribas Financial Markets Buys 68,234 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma’s SWOT analysis: stock shifts focus amid pipeline changes By Investing.com - Investing.com Nigeria
Sutro Biopharma’s SWOT analysis: stock shifts focus amid pipeline changes - Investing.com
Sutro Biopharma unveils best-in-class anti-tissue factor ADC - BioWorld MedTech
Sutro Biopharma, Inc. (NASDAQ:STRO) Given Consensus Rating of “Hold” by Brokerages - Defense World
Sutro Biopharma (NASDAQ:STRO) Price Target Cut to $0.80 by Analysts at Bank of America - Defense World
Sutro Biopharma (STRO): Analyst Lowers Price Target by 20% | STR - GuruFocus
Bank of America Adjusts Sutro Biopharma (STRO) Price Target | ST - GuruFocus
Dimensional Fund Advisors LP Buys 156,139 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma Reports Q1 2025 Earnings and Restructuring - TipRanks
Transcript : Sutro Biopharma, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 04 - marketscreener.com
Sutro Biopharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Sutro Biopharma, Inc. (NASDAQ:STRO) Shares Sold by Barclays PLC - Defense World
Sutro Biopharma Inc Reports Q1 2025 Revenue of $17.4M, Exceeding Estimates; EPS at -$0.91, Missing Projections - GuruFocus
Sutro Biopharma First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates - NewsBreak: Local News & Alerts
Sutro Biopharma earnings missed by $0.06, revenue topped estimates - Investing.com Canada
Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights - The Manila Times
Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights | STRO Stock News - GuruFocus
Sutro Biopharma, Inc. Advances ADC Pipeline Focus with Promising Preclinical Results and Strategic Reprioritization - Nasdaq
Financial Metrics Check: Sutro Biopharma Inc (STRO)’s Ratios for Trailing Twelve Months - DWinneX
Sutro Biopharma, Inc. (NASDAQ:STRO) Shares Bought by Invesco Ltd. - Defense World
Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Globe and Mail
Sutro Biopharma (NASDAQ:STRO) Earns Neutral Rating from HC Wainwright - The AM Reporter
Sutro Biopharma to Participate in Upcoming Investor Conferences - The Manila Times
Leading ADC Developer Sutro Biopharma to Present at Citizens and BofA Healthcare Conferences in May - Stock Titan
New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty - Benzinga
Sutro Biopharma (NASDAQ:STRO) Earns “Neutral” Rating from HC Wainwright - Defense World
Taking the lead: Sutro Biopharma Inc (STRO) - Sete News
Brokerages Set Sutro Biopharma, Inc. (NASDAQ:STRO) Price Target at $6.63 - The AM Reporter
Sutro Biopharma Inc [STRO] Investment Appeal on the Rise - knoxdaily.com
Demystifying Sutro Biopharma: Insights From 4 Analyst Reviews - Nasdaq
A stock that deserves closer examination: Sutro Biopharma Inc (STRO) - uspostnews.com
Sutro Biopharma to Highlight its Next-Generation Exatecan and Du - GuruFocus
Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025 - manilatimes.net
Sutro Biopharma Announces Poster Presentations on STRO-004 and XpressCF+® Platform at 2025 AACR Annual Meeting - Nasdaq
Revolutionary Dual-Payload Cancer Drug Shows Promise: Sutro's Next-Gen ADC Technology Impresses at AACR 2025 - Stock Titan
Sutro Biopharma Inc (STRO) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of “Hold” from Analysts - Defense World
Russell Investments Group Ltd. Has $183,000 Position in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
New fund will pressure flailing biotechs, as investor frustration boils over - Endpoints News
LPL Financial LLC Has $667,000 Stock Position in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma Inc (STRO) gets rating Downgrade from H.C. Wainwright - knoxdaily.com
Anchoring Your Portfolio: Is STRO Stock a Safe Harbor? - investchronicle.com
Take off with Sutro Biopharma Inc (STRO): Get ready for trading - Sete News
Sutro Biopharma Inc (NASDAQ: STRO) – Analysts’ Revisions Point To Positive Sentiment - Stocksregister
Biopharma restructurings reflect strategy of short-term pain for long-term gains - BioWorld MedTech
Benign Growth For Sutro Biopharma, Inc. (NASDAQ:STRO) Underpins Stock's 36% Plummet - simplywall.st
Sutro Biopharma stock hits 52-week low at $0.54 amid market challenges By Investing.com - Investing.com South Africa
Sutro Biopharma stock hits 52-week low at $0.54 amid market challenges - Investing.com Canada
Finanzdaten der Sutro Biopharma Inc-Aktie (STRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
3.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):